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ABSTRACT
Despite the accepted dogma that TRAIL kills only tumor cells and spares 
normal ones, we show in this study that mononuclear phagocytes are susceptible to 
recombinant TRAIL via caspase-dependent apoptosis. Human resting monocytes and 
in vitro-differentiated macrophages expressed substantial levels of the functional 
TRAIL receptors (TRAIL-R1 and TRAIL-R2), while neutrophils and lymphocytes mostly 
expressed the non-signaling decoy receptor (TRAIL-R3). Accordingly, exclusively 
monocytes and macrophages activated caspase-8 and underwent apoptosis upon 
recombinant TRAIL treatment. TRAIL-Rs were up-regulated by anti-inflammatory 
agents (IL-10, glucocorticoids) and by natural compounds (Apigenin, Quercetin, 
Palmitate) and their treatment resulted in increased TRAIL-induced apoptosis. 
In mice, the only signaling TRAIL-R (DR5) was preferentially expressed by blood 
monocytes rather than neutrophils or lymphocytes. In both mice and humans, 
Tumor-Associated Macrophages (TAM) expressed functional TRAIL-R, while resident 
macrophages in normal tissues did not. As a proof of principle, we treated mice 
bearing a murine TRAIL-resistant fibrosarcoma with recombinant TRAIL. We observed 
significant decrease of circulating monocytes and infiltrating TAM, as well as reduced 
tumor growth and lower metastasis formation. Overall, these findings demonstrate 
that human and murine monocytes/macrophages are, among leukocytes, uniquely 
susceptible to TRAIL-mediated killing. This differential susceptibility to TRAIL could 
be exploited to selectively target macrophages in tumors.
INTRODUCTION
In the last decade the inflammatory tumor 
microenviroment has been recognized as a hallmark of cancer 
and many efforts concentrated in counteracting or limiting 
this cancer-related inflammation [1–4]. Several studies have 
now established that local Tumor Associated Macrophages 
(TAM) fuel the build up of the inflammatory milieu and 
favour, rather than inhibit, disease progression [5, 6]. In 
fact, TAM density in human tumors is usually associated 
with poor patient prognosis and resistance to therapies [1, 
3, 7, 8]. Targeting of TAM for therapeutic purposes has 
been extensively pursued and is providing positive results 
in various experimental settings, either as monotherapy or 
combined with conventional and anti-angiogenic therapies. 
A number of different approaches has been used to target 
TAM in tumors: inhibition of their recruitment by using 
inhibitors of CCL2, alone or in combination therapy [9, 10]; 
the use of anti-CSF1R monoclonal antibodies or antagonists 
to the CSF1R tyrosine kinase [11–13]; as well as strategies 
aimed to their direct elimination, by inducing apoptosis or 
inhibition of vital pathways [14, 15], including inhibition of 
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the mTOR pathway [16–18]. Finally a different approach 
is the re-programming of their functional phenotype to re-
direct TAM towards cytotoxic effectors [19, 20]. Our group 
recently reported that trabectedin, a registered anti-tumor 
agent of marine origin, has interesting peculiar effects on the 
tumor micro-environment, in addition to block cell cycles in 
proliferating tumor cells. In vivo studies in mice and evidence 
in human patients revealed that at least part of its anti-tumor 
activity is mediated through the reduction of macrophages 
in tumors. Mechanistically, trabectedin selectively induced 
apoptosis in monocytes and macrophages via activation of 
caspase-8 [14]. Caspase-8 is the prime molecule involved in 
the extrinsic apoptotic pathway which initiates downstream 
of death receptors expressed on cell membranes.
Apoptosis activation is a tightly regulated process 
which involves a number of distinct functional receptors, 
some non-signaling or decoy receptors, in addition to 
several adaptor or regulatory proteins. In the case of the 
extrinsic apoptosis, two major classes of membrane-
associated death receptors have been identified: Fas, the 
receptor for the Fas ligand, and various receptors for the 
TNF-related apoptosis-inducing ligand (TRAIL). Among 
the latter, there are two functional receptors, TRAIL R1 
(DR4) and TRAIL R2 (DR5) having a death domain 
in their intracellular portion, and three non-signaling 
receptors, TRAIL R3 (Dcr1), TRAIL R4 (Dcr2) and 
osteoprotegerin (OPG), which lack the death domain 
and are unable to induce apoptosis, but compete with 
functional receptors for TRAIL binding [21–23]. Binding 
of TRAIL causes functional receptor oligomerization, with 
formation of DISC (Death Inducing Signalling Complex) 
and consequent activation of a caspase cascade that 
eventually leads to apoptotic cell death [21].
The current dogma is that TRAIL kills tumor 
cells in vitro and in vivo but spares normal cells that are 
insensitive to its apoptotic effect [24–28]. Our finding that 
the compound trabectedin was able to activate caspase-8 
and apoptosis selectively in monocytes, contradicted this 
dogma and raised the issue of a differential death receptor 
expression in distinct immune cell subsets. Some recent 
studies have shown that under conditions of bacterial 
or viral infections, immune cells become susceptible to 
TRAIL, as observed with HIV-infected T cells and alveolar 
macrophages during lung infection with Streptococcus 
pneumonia [29–31]. However, the vulnerability of primary 
leukocytes under normal homeostatic conditions is largely 
understudied. This prompted us to perform an in-depth 
analysis of death receptor expression and modulation 
in different leukocyte subsets with a special focus on 
mononuclear phagocytes in the tumor context.
Here we demonstrate that resting monocytes 
and macrophages differentially express signalling and 
decoy TRAIL-Rs and are susceptible to TRAIL-induced 
apoptosis. As a proof-of-principle, tumor-bearing mice 
treated with recombinant TRAIL had slowed tumor growth 
and reduced number of TAM in tumors.
RESULTS
Characterization of death receptors in human 
leukocyte subsets
Our initial observation that monocytes can be 
targeted by the anti-tumor agent trabectedin through 
extrinsic apoptosis [14] prompted us to define the 
expression and modulation of death receptors in human 
and mouse leucocyte subsets.
Freshly isolated purified human blood leukocytes 
were tested in flow cytometry; the Fas receptor 
was expressed at high levels in all leucocyte types 
(Figure S1A), while the expression of TRAIL-Rs was 
heterogeneous: the functional TRAIL-Rs (TRAIL-R1 and 
TRAIL-R2) were mainly expressed on monocytes whereas 
the decoy receptor (TRAIL-R3) was highly expressed on 
neutrophils and to a lesser extent on T lymphocytes (Figure 
1A-1B); of note, in lymphocytes activated with ionomycin 
and PMA, TRAIL-R3 was greatly increased (Figure S1B). 
Despite considerable heterogeneity among the donors, the 
results clearly indicated that the ratio between functional 
and decoy receptors, the key point determining TRAIL 
susceptibility, was in favor of functional TRAIL-Rs for 
monocytes and of the decoy receptor for neutrophils and 
lymphocytes. The other non-functional TRAIL-Rs (OPG 
and TRAIL-R4) were not significantly expressed in resting 
leukocytes (data not shown).
We next investigated TRAIL-Rs in monocyte 
subsets on the basis of the expression of CD14, MHC II 
and the chemokine receptor CX3CR1. TRAIL-R2 was 
similarly expressed among all monocyte subsets, while 
TRAIL-R1 was higher in CD14bright monocytes, with the 
exception of CD14bright/MHC IIdim cells. TRAIL-R3, which 
is usually very low, was higher in CD14bright/CX3CR1+ 
cells (Figure S1C).
In monocyte-derived macrophages, expression 
of all TRAIL-Rs was up-regulated compared to resting 
monocytes (Figure 1C-1D); of note, M1 and M2 polarized 
macrophages had similar expression levels, although M2 
cells had higher TRAIL-R2 compared to M1 macrophages.
In conclusion, functional TRAIL-Rs are mostly 
expressed on monocytes and macrophages, while the 
decoy R3 is preferentially expressed in neutrophils and 
lymphocytes.
TRAIL receptors in human resident tissue 
macrophages and tumor-associated macrophages
We next investigated death receptor expression 
in a series of normal and tumor tissues, by 
immunofluorescence. In normal human spleen and lungs, 
TRAIL-R2 and TRAIL-R3 were barely detectable (Figure 
2A-2B). A similar pattern was observed for TRAIL-R1 
(not shown). In human tumor tissues, TRAIL-R2 was 
expressed in the majority of macrophages in hepatic and 
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mammary carcinoma samples, and less frequently in 
colon carcinoma (Figure 2C), but it was not expressed 
by infiltrating lymphocytes and neutrophils. TRAIL-R3 
in tumor tissues was not expressed by any leukocyte 
type, with the exception of T lymphocytes in hepatic 
carcinoma (Figure 2D). Altogether these data show that 
tissue resident macrophages have no or low expression of 
functional TRAIL-Rs, while TAM within tumor tissues, 
but not other leukocytes, do express mainly TRAIL-R2.
TRAIL receptors are modulated by anti-
inflammatory stimuli in human monocytes/ 
macrophages
TRAIL receptor modulation was tested upon 
treatment in vitro of purified monocytes with several 
cytokines and prototypic stimuli. We observed that LPS, 
IL-1, TNFα, IL-6, as well as IL-4 and TGFβ did not 
modulate TRAIL-R1-2 or the decoy R3, which were 
actually slightly down-modulated. In contrast, IL-10 and 
glucocorticoids, strongly up-regulated TRAIL-R1-2 and, 
to a lesser extent, TRAIL-R3. IFNγ had a mild inducing 
effect on TRAIL-R1 and R3. The results are shown 
in Figure 3A and are expressed as fold increase over 
untreated cells.
In macrophages differentiated in vitro, IL-10, but 
not glucocorticoids, induced TRAIL-R up-regulation, 
while LPS, Pam-Cys and TGFβ had no effect (Figure 3B). 
Overall, these data indicate that TRAIL-Rs are positively 
modulated by anti-inflammatory mediators.
Monocytes and macrophages are susceptible to 
TRAIL treatment
The extrinsic apoptotic pathway starts with the 
activation of caspase-8, induced when a death ligand, 
Figure 1: Human monocytes and macrophages express functional TRAIL receptors. Flow cytometry analysis of TRAIL 
receptor (TRAIL-R) expression. A-B. Freshly isolated purified monocytes, lymphocytes and granulocytes (PMN); C-D. In vitro MCSF-
differentiated macrophages (M0) and polarized M1 (LPS, IFNγ) and M2 (IL-4) macrophages. In A and C, results are shown as % of positive 
cells (mean ± SE of 10 experiments). In B and D Representative plots are shown. Statistical analysis: *P < 0.05, ** P < 0.01, *** P < 0.001 
(Student’s t test).
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such as FasL, TNF or TRAIL, binds to its receptors. 
To understand whether the differential expression of 
TRAIL-Rs in leucocyte subsets corresponds to a different 
TRAIL susceptibility, we monitored caspase-8 activation 
in recombinant TRAIL-treated leukocytes by flow 
cytometry. We observed that lymphocytes and neutrophils 
were unable to activate caspase-8 when treated with 
TRAIL, while monocytes rapidly activated caspase-8 in 
a time dependent manner (Figure 4A). The involvement 
of functional TRAIL-Rs was confirmed by using anti-
TRAIL-R1-2 blocking antibodies that inhibited caspase-8 
activation, while anti-TRAIL-R3 or anti-Fas, used as 
negative controls, had no effect (Figure 4B). Activation 
of caspase-8 per se is not sufficient to induce apoptosis; 
we therefore analyzed the viability of TRAIL-treated 
monocytes over time. TRAIL induced monocyte apoptotic 
death in a time dependent manner, reducing their survival 
by 50% after 72h of treatment (Figure 4C). Furthermore, 
pre-treatment with IL-10 substantially sensitized 
monocytes to TRAIL-mediated death (Figure 4D).
Caspase-8 activation and mortality was induced 
also in cultured macrophages upon TRAIL treatment, as 
shown by immunofluorescence, but with less efficiency 
compared to monocytes (Figure 4E); this is probably due 
to their increased expression of TRAIL-R3 (Figure 1C) 
and intrinsic resistance to death due to their activated state.
Modulation of TRAIL receptors and apoptosis 
by natural compounds
It is known that some natural compounds, such 
as Palmitate and snail venom, are able to activate 
caspase-8 in a TRAIL-independent manner, through up-
regulation and/or aggregation of death receptors [32, 
33]. We investigated the effects of Apigenin, Palmitate, 
Quercitin, Indole-3-Carbinole (I3C) and the anti-tumor 
Figure 2: Human tumor-associated macrophages express TRAIL-R2. Immunofluorescence of TRAIL-R2 and TRAIL-R3 and 
leukocyte markers. A-B. Sections of un-diseased human spleen and lung; C-D. Sections of human mammary, hepatic and colon carcinoma. 
Macrophages (CD68), T cells (CD3) and granulocytes (myeloperoxidase) are marked in green, TRAIL-R2 and R3 in red and nuclei in blue. 
Macrophages from tumor tissues, but not from normal tissues, express TRAIL-R2 and do not express TRAIL-R3.
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Figure 3: Modulation of TRAIL receptors in human monocytes and macrophages. Glucocorticoids (10-7M, 24 hrs) induce 
up-regulation of TRAIL-R1-2 in monocytes while IL-10 (25 ng/ml, 24 hrs) induces up-regulation of TRAIL-R1-2 and to a lesser extent of 
TRAIL-R3 in monocytes (A) and macrophages (B). Results are shown as fold increase relative to untreated cells (mean ± SE of 3 different 
experiments). Statistical analysis: *P < 0.05, ** P < 0.01, *** P < 0.001 (Student’s t test).
agent trabectedin on purified human monocytes. These 
compounds, with the exception of I3C, indeed induced up-
regulation of TRAIL-Rs, in particular TRAIL-R2 (Figure 
5A). Higher expression of TRAIL-Rs was paralleled by 
increased cell mortality (Figure 5B).
To analyze the mechanism of ligand-independent 
death, we further investigated by immunofluorescence 
the expression of TRAIL-R2 and its localization on 
cell membranes. Upon treatment with Quercitin and 
trabectedin, the increased expression of TRAIL-R2 
correlated with its aggregation into lipid rafts (Figure 5C), 
in contrast Apigenin and Palmitate were not able to induce 
this aggregation and the increased death likely occurred 
via increased expression of receptors.
Characterization of TRAIL receptors in murine 
leucocyte subsets
In mice only one functional TRAIL-R is present, 
DR5 [34]. We first characterized DR5 expression in 
murine blood leukocyte subsets. As observed in human 
cells, only murine monocytes expressed appreciable 
levels of DR5, while the receptor was virtually absent in 
neutrophils, T and B cells (Figure 6A).
The analysis was performed in two mouse strains 
(C57BL/6 and DBA2J), with identical results (not shown). 
Furthermore, in vitro treatment of monocytes isolated from 
bone marrow with recombinant TRAIL decreased their 
viability (Figure S2A). The apoptotic effect was modest, 
compared to human monocytes, but consistently observed.
By immunofluorescence of normal tissues (spleen, 
skin, liver, lung) we observed that DR5 was not or rarely 
expressed by leukocytes, with the exception of the spleen, 
where it was present on F4/80+ macrophages as well as by 
some blood vessels, but not on Gr1+ myeloid cells (Figure 
6B). This finding was confirmed also on disaggregated 
splenocytes by flow cytometry (Figure S2B).
We next checked DR5 expression leukocytes 
infiltrating the transplantable murine fibrosarcoma (MN/
MCA1). TAM expressed substantial levels of DR5, but 
not other myeloid cells or vessels, as shown in Figure 
6C (flow cytometry on disaggregated cells) and in Figure 
6D (immunofluorescence on tumor sections). As we 
observed that not all F4/80+ macrophages were DR5+, 
we investigated other macrophage markers. In the spleen 
of tumor-bearing mice (Figure 6E) and in tumor tissues 
(Figure 6F), DR5 was predominantly expressed by CD206+ 
and Tie2+ macrophages but not by F4/80+ MHCII+ cells.
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Figure 4: rhTRAIL induces caspase-8 activation and apoptosis selectively in human monocytes and macrophages. 
A. Activation of caspase-8 analyzed by flow cytometry after rhTRAIL (SuperKiller) treatment (300 ng/ml); monocytes but not granulocytes and 
lymphocytes activate caspase-8. Results are shown as % of positive cells (mean ± SE of 5 different donors for monocytes and lymphocytes, 
2 for granulocytes). B. Activation of caspase-8 in monocytes analyzed by flow cytometry; activation is blocked by anti-TRAIL-R1/R2 
antibodies. Results are shown as fold change relative to untreated cells. C. Cell viability of monocytes treated with rhTRAIL for up to 72 
hrs evaluated with Annexin/PI staining by flow cytometry; results are shown as % of live cells (Mean ± SE of 4 experiments). D. Monocyte 
death upon 24 hrs treatment with rhTRAIL (300 ng/ml) and IL-10 (25 ng/ml) alone or in combination; results are shown as % of dead 
cells (Mean ± SE of 3 experiments). Statistical analysis: *P < 0.05, ** P < 0.01, *** P < 0.001 (Student’s t test). E. Immunofluorescence 
analysis of Caspase-8 activation in in vitro differentiated macrophages after rhTRAIL treatment (300 ng/ml, 12 hrs); Images were taken 
using confocal microscope: nuclei are shown in blue, PI in red and cleaved-caspase 8 in green.
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Figure 5: Modulation of TRAIL receptors in human monocytes by natural compounds. A. Up-regulation of TRAIL-R 
expression upon treatment with Quercitin, Apigenin, Palmitate and Trabectedin for 24 hrs; results are shown as fold increase relative to 
untreated monocytes (mean±SE of 5 experiments). Indole-3-carbinole (I3C) has no effect on TRAIL-R modulation. B. Quercitin, Apigenin, 
Palmitate and Trabectedin induce cell death after 12hrs treatment; results are shown as % of dead cells (mean ± SE of 5 experiments). 
C. Immunofluorescence analysis of TRAIL-R2 (light blue) and lipid rafts (red) in treated monocytes. Quercitin and Trabectedin induce 
TRAIL-R2 co-localization into lipid rafts. Statistical analysis: *P < 0.05, ** P < 0.01, *** P < 0.001 (Student’s t test).
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Figure 6: Murine monocytes and macrophages express the functional TRAIL receptor DR5. A. Flow cytometry analysis of 
murine TRAIL-R (DR5) in blood monocytes, granulocytes, T and B lymphocytes; results are shown as % of positive cells relative to total 
CD45+ cells (mean±SE of 29 blood samples). B. Immunofluorescence analysis of DR5, macrophages (F4/80), granulocytes (Ly6G) and 
endothelial cells (CD31) in normal murine tissues, (DR5 in red, F4-80/Ly6G/CD31 in green and nuclei in blu). C. DR5 expression in TAM 
and in MDSC from tumor tissues; results are shown as % of positive cells (Mean ± SD of 3 experiments); D. immunofluorescence analysis 
of DR5 in fibrosarcoma tumor tissues (DR5 in red, F4-80/Ly6G/CD31 in green and nuclei in blu). E-F. DR5 expression in CD206+, Tie2+, 
MHCII+ macrophages from spleen (E) and tumor (F); results are shown as % of positive cells (Mean ± SD of 3 experiments). Statistical 
analysis: *P < 0.05, ** P < 0.01, *** P < 0.001 (Student’s t test).
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Overall, these data indicate that, also in mice, 
the functional TRAIL-R DR5 is mainly expressed by 
monocytes and macrophages, including TAM.
Targeting of tumor macrophages in vivo by 
recombinant TRAIL
In order to understand whether the TRAIL-R 
pathway could be used to target TAM in the tumor micro-
environment, we treated mice transplanted with the MN/
MCA1 fibrosarcoma with recombinant TRAIL. We 
previously reported that this murine fibrosarcoma is highly 
infiltrated by macrophages, which have a significant 
accelerating effect on tumor progression [14, 35]. We first 
checked the susceptibility of fibrosarcoma cells to TRAIL 
treatment in vitro and found that they were intrinsically 
resistant, while the anti-tumor agent trabectedin, used as 
positive death inducer, considerably reduced cell viability 
(Figure S3A). TRAIL treatment of mice significantly 
impaired tumor growth and spontaneous lung metastasis 
formation (Figure 7A). Resistance of tumor cells to 
TRAIL, after in vivo growth and treatment, was confirmed 
also ex vivo on cultured cells (Figure S3B). In TRAIL-
treated mice, the number of blood monocytes, in particular 
the Ly6Chigh subset, was significantly decreased 48 hours 
post-treatment (Figure 7C), as well as the number of TAM 
in tumors (especially the Ly6Cint subset) as detected by 
flow cytometry (Figure 7D) and by immunohistochemistry 
(Figure 7E). Figure 7E also shows the marked reduction 
of CD206+ TAM, the most expressing DR5 subsets; 
furthermore, the vessel network in treated tumors was 
appreciably reduced.
Taken together these data demonstrate, in a context 
where tumor cells are not susceptible, that treatment 
with TRAIL targets in vivo monocytes/macrophages and 
significantly reduces tumor progression.
DISCUSSION
In this study we performed a comprehensive 
analysis of TRAIL receptor expression and function in 
blood leukocyte subsets and in tissue resident and tumor-
associated macrophages, in mice and humans.
In blood leukocytes, functional TRAIL-Rs 
(TRAIL-R1-2) are exclusively expressed by monocytes 
while neutrophils and T cells have only the decoy 
receptor TRAIL-R3. The biological significance of this 
clear-cut segregation is unclear. We can speculate that it 
is reasonable that monocytes must be kept under strict 
control, being potentially very reactive cells and with a 
relatively long life span. Neutrophils, instead, have a 
life span of few hours in the circulation and the decoy 
TRAIL-R3 could be helpful to maintain their integrity. 
Finally, T lymphocytes bear memory for antigens and 
must be protected from death. Of note, the other death 
receptor: Fas, is equally expressed and at high levels on 
all leukocyte subsets. Thus, while functional TRAIL-Rs 
are present only on monocytes, Fas is present also on 
neutrophils and T lymphocytes. The regulation of cell 
susceptibility to Fas ligand-induced apoptosis could be at 
the ligand rather than at the receptor level, as it appears to 
be for TRAIL; in fact FasL is produced and regulated in a 
strict manner, while TRAIL ligand is usually constitutively 
expressed by several tissues [24, 25, 27, 28], although it 
can be induced in immune cells upon stimulation with 
LPS, IFNβ or IFNγ [36].
Death pathways impact importantly on the immune 
system development and regulation. TRAIL-deficient 
mice have been reported to have defects in the thymic 
negative selection and control of central tolerance, with 
consequences for the development of autoimmune diseases 
[37, 38] although not confirmed in other studies [39]. 
Sedger et al. reported that control of aberrant lymphocyte 
expansion requires both FasL and TRAIL and only the 
double KO mice show a marked lymphoproliferative 
disease and severe autoimmunity [40]. Thus TRAIL in 
tandem with FasL are important to control lymphocyte 
homeostasis and to limit autoimmunity. As far as innate 
immunity, and in line with our data on monocytes/
macrophages, TRAIL-R KO mice were reported to have 
boosted innate immune responses with increased levels of 
IL-12, IFN-α, and IFN-γ after pathogen infection [41].
The ligand TRAIL has been reported to mediate also 
non-apoptotic effects [42]. Besides the activation of death 
receptors and downstream caspase-dependent apoptosis, 
TRAIL can activate pro-survival pathways including 
NF-kB, PI3K, MAPK [43, 44]. Furthermore, TRAIL-
Rs have been implicated in liver-associated macrophage 
inflammation leading to obesity and insulin resistance 
[45]. On the other hand, other studies suggested that 
TRAIL can negatively regulate the inflammatory response 
[46–48]. In this study we investigated whether TRAIL 
could modify the constitutive or LPS-induced production 
of several inflammatory mediators (e.g. IL-1β, IL-6, 
CXCL8) in human monocytes, but we did not observe any 
significant modulation (data not shown).
TRAIL-Rs on leukocytes can be up-regulated under 
infectious conditions, such as in T cells infected by the HIV 
virus and alveolar macrophages infected by Streptococcus 
pneumonia [29, 31]. In our study, the analysis of TRAIL-R 
modulation on monocytes and macrophages revealed that 
pro-inflammatory cytokines have no significant role, 
while cytokines with anti-inflammatory properties such as 
IL-10 and glucocorticoids strongly up-regulate TRAIL-
Rs. A possible scenario could be that at the peak of an 
acute inflammation, when inflammatory monocytes have 
concluded their role, endogenous corticoids and IL-10, 
involved in the resolution phase, increase the number of 
TRAIL-Rs on monocytes and facilitate their apoptotic 
death and final disposal. If this is the case, it would be of 
interest to investigate TRAIL-R expression in monocytes/
Oncotarget41671www.impactjournals.com/oncotarget
Figure 7: In vivo effects of TRAIL treatment on TAM and tumor growth. A-B. Anti-tumor effect of TRAIL treatment (0,01 g/
kg) on primary tumor growth and spontaneous lung metastases (mean ±SE, 7 mice per group; representative experiment of two performed 
with similar results. C. Flow cytometry analysis of blood monocytes from TRAIL-treated or untreated mice; monocytes and in particular 
Ly6CHigh expressing monocytes are significantly reduced after 48 hrs treatment. D. Flow cytometry analysis of TAM from TRAIL-treated 
or untreated mice; TAM and in particular the Ly6CInter subset are significantly reduced after treatment; in both C and D results are shown as 
% of positive cells relative to total CD45+ cells (mean ±SE, 7 mice per group) E. Immunohistochemistry of tumor sections from TRAIL-
treated and untreated mice stained for F4/80, CD31 and CD206. The immunoreactive area for macrophages (F4/80, CD206) and number 
of vessels (CD31) are shown on the right panels. Results are calculated as mean from five microscope fields for each sample, 7 mice per 
group. Images were analyzed using Image-Pro Analyzer software. Original magnification 20X. Statistical analysis: *P < 0.05, ** P < 0.01, 
*** P < 0.001 (Student’s t test).
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macrophages under conditions of chronic non-resolving 
inflammation.
The other interesting result of this study was the 
finding that, in both mice and humans, tissue resident 
macrophages do not usually express TRAIL-Rs (with the 
exception of murine splenocytes), while macrophages 
infiltrating the tumor micro-environment are clearly 
TRAIL-R positive. This divergent expression could be 
explained with the different origin of resident peripheral 
macrophages (mainly embryonic precursors derived from 
the yolk sac) and of TAM (circulating monocytes, which 
express TRAIL-R1-2) [49]. Furthermore, the tumor micro-
environment is usually rich in IL-10, which is the major 
regulator of TRAIL-Rs among the factors tested in this 
study.
Another myeloid cell type associated to cancer is 
the heterogeneous population of MDSC. Condamine et 
al reported that MDSC cells from tumor-bearing mice 
are susceptible to TRAIL-induced apoptosis and that 
under conditions of endoplasmic reticulum (ER) stress 
the DR5 receptor is up-regulated [50]. In our study, 
MDSC from spleens of tumor-bearing mice expressed 
low levels of DR5 and to a much lower extent compared 
to macrophages. It may possible that different isolating 
techniques and distinct anti-DR5 antibodies may account 
for this discrepancy. In the tumor micro-environment, 
Wilson et al. reported that endothelial cells in cancer-
associated vessels express DR5 and that TRAIL may 
function as a tumor vascular disruption agent [51]. In 
our fibrosarcoma model, we only sporadically observed 
receptor positivity co-localized with CD31 staining; 
however, a marked effect was found on the vessel 
network after in vivo TRAIL treatment, although it cannot 
be excluded that this is an indirect effect caused by the 
reduced macrophages.
The finding that TAM have functional TRAIL-
Rs bears interest for therapeutic implications. In the last 
few years it has become increasingly clear that targeting 
of tumor macrophages is a promising approach to limit 
tumor progression. The most studied strategies have used 
inhibitors to the receptor kinase specific for mononuclear 
phagocytes (M-CSF-R). Several different inhibitors are 
now available; including monoclonal antibodies and small 
compounds, and their effects in experimental mouse tumor 
models is highly promising. Another approach is to limit 
the recruitment of circulating monocytes at tumor sites by 
interfering with their response to chemoattractants [13, 
52], or to re-activate macrophage cytotoxic potential with 
agonist anti-CD40 antibodies, TLR agonists or low dose 
irradiation [53, 54].
As a proof of principle that TRAIL-Rs on TAM 
constitute an interesting molecular target to induce 
their apoptosis, we treated tumor-bearing mice with 
recombinant TRAIL and observed a significant decrease 
of TAM and of circulating monocytes; even if tumor cells 
were completely resistant to TRAIL-induced apoptosis, 
a significant slow down of primary tumor growth was 
noted, as well as a reduction in the number of spontaneous 
lung metastasis. These results, therefore, constitute the 
rationale to consider TRAIL therapy as an approach to 
target TAM, even in contexts where tumor cells have 
acquired resistance to TRAIL although this remains to be 
demonstrated in more relevant clinical settings.
In general, TAM have a M2-like phenotype but their 
heterogeneity is emerging in the last years and different 
patterns can be found in different tumor types as well 
as along tumor progression [4, 55]. In our fibrosarcoma 
model, the receptor DR5 was predominantly expressed by 
CD206+ Tie2+ TAM rather than by the fewer MHC IIhigh 
TAM; thus DR5+ TAM displayed a typical phenotype 
of M2-polarized macrophages [7, 56]. This was in part 
consistent with the results of in vitro differentiated human 
macrophages where TRAIL-R2 was indeed higher in M2 
than in M1 macrophages.
There is considerable interest in the potential role 
of TRAIL in cancer therapy [24, 26, 27, 57–59]. Although 
in the past 15 years the clinical results have been quite 
disappointing, as many tumors showed intrinsic or 
acquired resistance to TRAIL treatment, new recombinant 
forms of TRAIL and agonistic antibodies are under 
clinical evaluation for a number of different tumors [26, 
57, 58]. To counteract TRAIL-resistance in tumor cells, 
two strategies have been implemented: combining TRAIL 
therapy with other anti-tumor therapies [60] or with 
natural compounds that increase cell susceptibility [61]. 
For instance, Apigenin, Quercitin and Palmitate have been 
shown to increase the expression of functional TRAIL-
Rs on the surface of tumor cells and to restore TRAIL-
induced apoptosis [32, 62, 63]. We found in this study 
that these natural compounds, as well as trabectedin, up-
regulated TRAIL-Rs on monocytes, and in some cases 
were able to induce co-localization of TRAIL-Rs into lipid 
rafts and trigger apoptotic death.
In conclusion, the expression of functional TRAIL-
Rs on cells of the mononuclear phagocyte system and 
their susceptibility to apoptosis indicate that TRAIL-
based therapies could be an alternative approach to target 
macrophages in tumors.
MATERIALS AND METHODS
Drugs and stimuli
For in vitro experiments Recombinant Super Killer 
Trail (Human: Enzo Lifesciences; Mouse: Adipogene) was 
dissolved in PBS-/- 1%BSA, kept at -80°C and used 300 
ng/ml.
For in vivo experiments Trail Recombinant 
KillerTRAIL (Alexis) was resuspended in PBS-/- and used 
10 mg/kg i.p every 3 days for 2 weeks.
Glucocorticoids (MP Biomedicals) were used 
100uM; hIL-10, hIL-1, hIL-2, hIL-4, hIL-6, hTNFα, 
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hINFγ, hTGFβ (Peprotech) 25 ng/ml; LPS (Alexis) 100 
ng/ml; Pam3Cys (Vinci Biochem) 2 ug/ml according to 
the manufacture’s instructions.
Apigenin, Quercitin (Indena) and trabectedin 
(Pharmamar) were resuspended in DMSO and used 40uM, 
400uM and 10 nM respectively. Palmitate (SIGMA), 
Indole-3-Carbinole (I3C) resuspended in DMSO and used 
800uM and 100uM respectively.
In vivo experiment
The transplantable MNMCA-1 mouse fibrosarcoma 
were inoculated intramuscularly (5x104 cells) in C57/
BL/6J mice (Charles River - Calco, Como Italy) and tumor 
growth was observed over 3 weeks. All mice were used 
between 6-10 week of age.
Mice, Tumors, and Primary mouse Cells were used 
in compliance with national (4D.L.N.116, G.U., suppl. 
40, 18-2-1992) and international law and policies (EEC 
Council Directive 86/609, OJ L 358, 1, 12-12-1987; NIH 
Guide for the Care and Use of Laboratory Animals, US 
National Research Council, 1996). This investigation was 
approved by the Animal Care and Use Committee of the 
Humanitas Clinical and Research Center.
Cell isolation, cell culture and tissue samples
Human monocytes, neutrophils, and T-lymphocytes 
from blood of healthy donors were purified through 
density gradients, as described in Allavena [64], from 
buffy-coats. Human macrophages were differentiated 
in vitro from blood monocytes cultured with 25 ng/ml 
M-CSF for 5 days and then polarized with LPS (100 ng/
ml) + IFN-γ (500 U/ml) for M1 macrophages and with 
IL-4 (20 ng/ml) to obtain M2 ones. Human lymphocytes 
were antivated in vitro with Ionomycin (500 ng/ml) and 
PMA (50 ng/ml).
Mouse blood cells were collected from the eye vein 
of anesthetized mice and splenocytes from disaggregated 
spleen and filtered through Falcon strainers. Mouse tumors 
were cut into small pieces, disaggregated with collagenase 
(0.5 mg/ml), and filtered through strainers.
Human tumor tissues and adjacent un-diseased 
tissues were obtained from patients who underwent 
surgical treatment in our Institute. Murine normal tissues 
(spleen, skin, liver, lungs) were obtained from 6 weeks old 
C57/BL/6J mice from the animal house of our institute. 
Samples were stained with specific antibodies.
Antibodies
To study the expression of death receptors in human 
leucocytes, cells were resuspended in PBS-/- 1X 1% FBS 
and stained with anti-human TRAIL-R1, TRAIL-R2 (Enzo 
Lifesciences), anti-human TRAIL R3 (R&D Systems) 
and anti-human Fas (Millipore) used according to the 
manufacture’s instructions. To block their activity were 
used recombinant human Trail R1/R2 Fc chimera (R&D 
Systems), anti-human TRAIL R3 (R&D Systems) and 
anti-human Fas (Millipore).
To analyze cell phenotype in mouse blood, spleen 
and tumor were used PerCp-Rat CD45 (30F11), FITC 
Hamster CD3 (145-2C11), PE Rat Ly6C and Ly6C 
(RB6-8C5), FITC Rat Ly6C (AL-21), PE-Cy7 Rat Ly-
6G (1A8), FITC Rat I-A/I-E (2G9) as well as relative 
control antibody, streptavidin dye conjugated (APC) (BD 
Biosciences);Anti-mouse PE CD115 (AFS98), Alexa 
Fluor 647 CD19 (1D3), PE Rat CD202b/Tie2 (Tec4) 
(eBioscience); Anti-mouse PE F4/80 (A3-1), FITC Rat 
CD206 (MR5D3) (AbD Serotec); Biotin-RatCD253(DR5) 
(N2B2) (Miltenyi Biotec) and finally, Pacific Blue-Rat 
CD11b (M1/70) (Biolegend). Labeled cells were fixed 
in PBS-/- 1X 1% formalin. After staining procedures, 
acquisition was performed by FACS CantoII instrument 
(BD Biosciences) and analyzed by FACS Diva and FlowJo 
software version 6.1.1 (BD Biosciences)
To perform immunofluorescence on human 
tissues were used anti-TRAIL-R1, TRAIL-R2 (Enzo 
Lifesciences), anti- TRAIL R3 (R&D Systems), rabbit 
CD68 (PGM1), rabbit myeloperoxidase, and rabbit CD3 
purchased by DAKO; Lipid rafts are detected using 
Vibrant Lipid Raft Labeling Kits (molecular brobe) used 
according to the manufacture’s instructions.
For mouse tissues were used goat TRAIL R2 
(DR5), goat CD31 (R&D Systems), rat Ly-6G (1A8) (BD 
Pharmingen) and rat F4/80 (Serotec).
Apoptosis and cell death analysis
Apoptosis was evaluated through Annexin V/PI 
staining using the specific detection kit (Immunostep) used 
according to the manufacture’s instructions.
To evaluate caspase8 activation were used anti-
human cleaved-caspase8 (18C8) anti-mouse cleaved-
caspase8 Xp Rabbit Mab (D5B2) (Cell signaling) and 
Fixation/Permeabiliation solution kit (BD Biosciences) 
according to the manufacture’s instructions. Labeled cells 
were fixed in PBS-/- 1X 1% formalin.
Statistical analysis
Statistical analysis was performed using a paired 
Student’s t-test. P-values of less than 0.05 were considered 
significant
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